CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
ADVL0821 COG A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody; IND# 100947; NSC# 742460) in Children with Relapsed/Refractory Solid Tumors: A COG Groupwide Phase II Study Pediatric CIRB
ADVL0921 COG A Phase II Study of MLN8237 (IND# 102984); a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias Pediatric CIRB
ADVL1121 COG A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma; Wilms Tumor; Hepatocellular Carcinoma; and Papillary Thyroid Carcinoma Pediatric CIRB
ADVL1221 COG A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors Pediatric CIRB
ADVL1314 COG A Phase 1 Study of Eribulin Mesylate (E7389; IND #116;292); A Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS); Including Lymphomas: A Participation Limited to the COG Phase 1 Consortium Pediatric CIRB
ADVL1315 COG A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA; 123101) in Children with Recurrent or Refractory Solid Tumors Pediatric CIRB
ADVL1412 COG A Phase 1/2 Study of Nivolumab (IND# 124729) in Children; Adolescents; and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Pediatric CIRB
ADVL1414 COG A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors Pediatric CIRB
ADVL1416 COG A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors Pediatric CIRB
ADVL1513 COG A Phase 1 Study of Entinostat; An Oral Histone Deacetylase Inhibitor; In Pediatric Patients with Recurrent or Refractory Solid Tumors; Including CNS Tumors and Lymphoma Pediatric CIRB